{"name":"Kyowa Kirin","slug":"kyowa-kirin","ticker":"4151.T","exchange":"TSE","domain":"kyowakirin.com","description":"Kyowa Kirin Co., Ltd.  is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and was among the 40 largest in the world by revenue in 2012. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.","hq":"Tokyo, Japan","founded":1949,"employees":"5161","ceo":"Masashi Miyamoto","sector":"Rare Disease / Oncology / Nephrology","stockPrice":2363,"stockChange":5.5,"stockChangePercent":0.23,"marketCap":"$7.8B","metrics":{"revenue":3228051613.363359,"revenueGrowth":13.1,"grossMargin":73.8,"rdSpend":0,"netIncome":460952408.19746405,"cash":1577589363.1350243,"dividendYield":2.97,"peRatio":18.5,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Poteligeo","genericName":"MOGAMULIZUMAB","slug":"mogamulizumab","revenue":300000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"1981-01-01","label":"Mitozytrex first approved","drug":"Mitozytrex","drugSlug":"mitomycin","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Fareston first approved","drug":"Fareston","drugSlug":"toremifene","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Poteligeo first approved","drug":"Poteligeo","drugSlug":"mogamulizumab","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Nourianz first approved","drug":"Nourianz","drugSlug":"istradefylline","type":"approval","sentiment":"positive"},{"date":"2026-07-19","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2026-07-19","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-01-02","label":"Mitozytrex patent expiry (Compound)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-02-01","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-05-21","label":"Mitozytrex patent expiry (Method of Use)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Method of Use)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Method of Use)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Method of Use)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Poteligeo patent cliff ($1.4B at risk)","drug":"Poteligeo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":300000000,"percentOfTotal":100,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Poteligeo","genericName":"MOGAMULIZUMAB","slug":"mogamulizumab","indication":"Mycosis fungoides","status":"marketed","revenue":300000000},{"name":"Fareston","genericName":"TOREMIFENE","slug":"toremifene","indication":"Metastatic Breast Carcinoma","status":"marketed"},{"name":"Mitozytrex","genericName":"MITOMYCIN","slug":"mitomycin","indication":"Disseminated adenocarcinoma of the stomach or pancreas","status":"marketed"},{"name":"KW-2246","genericName":"KW-2246","slug":"kw-2246","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Poteligeo","genericName":"Poteligeo","slug":"poteligeo","indication":"Mycosis fungoides","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"immunology","drugs":[{"name":"KHK4827-Active","genericName":"KHK4827-Active","slug":"khk4827-active","indication":"Other","status":"marketed"},{"name":"KHK4577","genericName":"KHK4577","slug":"khk4577","indication":"Other","status":"phase_2"},{"name":"KRN23","genericName":"KRN23","slug":"krn23","indication":"X-linked hypophosphatemia (XLH) in children and adults","status":"marketed"},{"name":"KRN321","genericName":"KRN321","slug":"krn321","indication":"Other","status":"phase_2"},{"name":"CRYSVITA","genericName":"BUROSUMAB-TWZA","slug":"burosumab-twza","indication":"Familial x-linked hypophosphatemic vitamin D refractory rickets","status":"marketed"},{"name":"Granisetron IV","genericName":"Granisetron IV","slug":"granisetron-iv","indication":"Other","status":"phase_1"},{"name":"KHK6640","genericName":"KHK6640","slug":"khk6640","indication":"Other","status":"phase_1"},{"name":"KK2845_1","genericName":"KK2845_1","slug":"kk2845-1","indication":"Other","status":"phase_1"},{"name":"KK2845_3","genericName":"KK2845_3","slug":"kk2845-3","indication":"Other","status":"phase_1"},{"name":"KK2845_6","genericName":"KK2845_6","slug":"kk2845-6","indication":"Other","status":"phase_1"},{"name":"KW-6356 Middle Dose","genericName":"KW-6356 Middle Dose","slug":"kw-6356-middle-dose","indication":"Other","status":"phase_1"},{"name":"KW-6356 X Dose","genericName":"KW-6356 X Dose","slug":"kw-6356-x-dose","indication":"Other","status":"phase_1"},{"name":"KW-6500","genericName":"KW-6500","slug":"kw-6500","indication":"Growth hormone deficiency in adults","status":"phase_3"},{"name":"Oral Phosphate Supplement","genericName":"Oral Phosphate Supplement","slug":"oral-phosphate-supplement","indication":"Other","status":"marketed"},{"name":"active vitamin D","genericName":"active vitamin D","slug":"active-vitamin-d","indication":"Treatment of hypocalcemia in patients with vitamin D deficiency or insufficiency","status":"phase_3"},{"name":"saxaglipitin","genericName":"saxaglipitin","slug":"saxaglipitin","indication":"Other","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"cardiovascular","drugs":[{"name":"AMG531","genericName":"AMG531","slug":"amg531","indication":"Thrombocytopenia","status":"phase_2"},{"name":"KHK4827","genericName":"KHK4827","slug":"khk4827","indication":"Thromboembolism prevention (in development)","status":"phase_3"},{"name":"KHK7791","genericName":"KHK7791","slug":"khk7791","indication":"Thrombotic disorders and stroke prevention (Phase 3 development)","status":"phase_3"},{"name":"Plasma-derived antithrombin","genericName":"Plasma-derived antithrombin","slug":"plasma-derived-antithrombin","indication":"Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery","status":"phase_3"},{"name":"KHK7580","genericName":"KHK7580","slug":"khk7580","indication":"Thromboembolism prevention","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"infectious","drugs":[{"name":"Istradefylline (KW-6002)","genericName":"Istradefylline (KW-6002)","slug":"istradefylline-kw-6002","indication":"Parkinson's disease with motor fluctuations in patients on levodopa therapy","status":"phase_3"},{"name":"Nourianz","genericName":"ISTRADEFYLLINE","slug":"istradefylline","indication":"Parkinson's disease","status":"marketed"},{"name":"OPC-262","genericName":"OPC-262","slug":"opc-262","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"EN3267","genericName":"EN3267","slug":"en3267","indication":"Immunoglobulin A nephropathy (IgAN)","status":"phase_3"},{"name":"KK8398","genericName":"KK8398","slug":"kk8398","indication":"Autoimmune/inflammatory conditions (specific indication under investigation in phase 3)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"KHK4083","genericName":"KHK4083","slug":"khk4083","indication":"Treatment of type 2 diabetes","status":"phase_2"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"KW-2246 (fentanyl citrate)","genericName":"KW-2246 (fentanyl citrate)","slug":"kw-2246-fentanyl-citrate","indication":"Moderate to severe pain (specific indication under investigation in phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"Poteligeo","genericName":"MOGAMULIZUMAB","slug":"mogamulizumab","phase":"marketed","mechanism":"Poteligeo works by binding to the C-C chemokine receptor type 4, which is involved in the migration and proliferation of T-cells.","indications":["Mycosis fungoides","Peripheral T-cell lymphoma","Primary cutaneous T-cell lymphoma"],"catalyst":""},{"name":"KHK4827-Active","genericName":"KHK4827-Active","slug":"khk4827-active","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMG531","genericName":"AMG531","slug":"amg531","phase":"phase_2","mechanism":"AMG531 is a thrombopoietin receptor agonist.","indications":["Thrombocytopenia"],"catalyst":""},{"name":"EN3267","genericName":"EN3267","slug":"en3267","phase":"phase_3","mechanism":"EN3267 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 axis to reduce inflammatory cell recruitment and activation.","indications":["Immunoglobulin A nephropathy (IgAN)"],"catalyst":""},{"name":"Fareston","genericName":"TOREMIFENE","slug":"toremifene","phase":"marketed","mechanism":"Fareston works by binding to estrogen receptors in the body, which can help reduce the growth of breast cancer cells.","indications":["Metastatic Breast Carcinoma"],"catalyst":""},{"name":"KHK4577","genericName":"KHK4577","slug":"khk4577","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KHK4827","genericName":"KHK4827","slug":"khk4827","phase":"phase_3","mechanism":"KHK4827 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.","indications":["Thromboembolism prevention (in development)"],"catalyst":""},{"name":"KHK7791","genericName":"KHK7791","slug":"khk7791","phase":"phase_3","mechanism":"KHK7791 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key coagulation cascade enzyme, thereby reducing thrombotic risk.","indications":["Thrombotic disorders and stroke prevention (Phase 3 development)"],"catalyst":""},{"name":"KK8398","genericName":"KK8398","slug":"kk8398","phase":"phase_3","mechanism":"KK8398 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 signaling pathway to reduce inflammatory cell recruitment and activation.","indications":["Autoimmune/inflammatory conditions (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"KRN23","genericName":"KRN23","slug":"krn23","phase":"marketed","mechanism":"KRN23 is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23), restoring phosphate reabsorption and vitamin D metabolism in patients with X-linked hypophosphatemia.","indications":["X-linked hypophosphatemia (XLH) in children and adults"],"catalyst":""},{"name":"KRN321","genericName":"KRN321","slug":"krn321","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mitozytrex","genericName":"MITOMYCIN","slug":"mitomycin","phase":"marketed","mechanism":"Indoleamine 2,3-dioxygenase 1","indications":["Disseminated adenocarcinoma of the stomach or pancreas","Palliative treatment for disseminated adenocarcinoma"],"catalyst":""},{"name":"Plasma-derived antithrombin","genericName":"Plasma-derived antithrombin","slug":"plasma-derived-antithrombin","phase":"phase_3","mechanism":"Plasma-derived antithrombin is a protein that inhibits the coagulation cascade by binding to and neutralizing thrombin and other coagulation factors.","indications":["Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery"],"catalyst":""},{"name":"CRYSVITA","genericName":"BUROSUMAB-TWZA","slug":"burosumab-twza","phase":"marketed","mechanism":"Fibroblast growth factor 23","indications":["Familial x-linked hypophosphatemic vitamin D refractory rickets","Osteomalacia"],"catalyst":""},{"name":"Granisetron IV","genericName":"Granisetron IV","slug":"granisetron-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Istradefylline (KW-6002)","genericName":"Istradefylline (KW-6002)","slug":"istradefylline-kw-6002","phase":"phase_3","mechanism":"Istradefylline is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the basal ganglia, thereby enhancing dopaminergic motor control.","indications":["Parkinson's disease with motor fluctuations in patients on levodopa therapy"],"catalyst":""},{"name":"KHK4083","genericName":"KHK4083","slug":"khk4083","phase":"phase_2","mechanism":"KHK4083 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"KHK6640","genericName":"KHK6640","slug":"khk6640","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KHK7580","genericName":"KHK7580","slug":"khk7580","phase":"phase_3","mechanism":"KHK7580 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.","indications":["Thromboembolism prevention","Atrial fibrillation stroke prevention"],"catalyst":""},{"name":"KK2845_1","genericName":"KK2845_1","slug":"kk2845-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KK2845_3","genericName":"KK2845_3","slug":"kk2845-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KK2845_6","genericName":"KK2845_6","slug":"kk2845-6","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KW-2246","genericName":"KW-2246","slug":"kw-2246","phase":"phase_3","mechanism":"KW-2246 is a humanized monoclonal antibody that binds to and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"KW-2246 (fentanyl citrate)","genericName":"KW-2246 (fentanyl citrate)","slug":"kw-2246-fentanyl-citrate","phase":"phase_3","mechanism":"KW-2246 is a fentanyl citrate formulation that binds to opioid receptors in the central nervous system to produce analgesia and pain relief.","indications":["Moderate to severe pain (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"KW-6356 Middle Dose","genericName":"KW-6356 Middle Dose","slug":"kw-6356-middle-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KW-6356 X Dose","genericName":"KW-6356 X Dose","slug":"kw-6356-x-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KW-6500","genericName":"KW-6500","slug":"kw-6500","phase":"phase_3","mechanism":"KW-6500 is a long-acting growth hormone secretagogue that stimulates growth hormone release by activating ghrelin receptors.","indications":["Growth hormone deficiency in adults"],"catalyst":""},{"name":"Nourianz","genericName":"ISTRADEFYLLINE","slug":"istradefylline","phase":"marketed","mechanism":"Nourianz works by blocking the adenosine receptor A2a, which helps to increase dopamine levels in the brain.","indications":["Parkinson's disease"],"catalyst":""},{"name":"OPC-262","genericName":"OPC-262","slug":"opc-262","phase":"phase_3","mechanism":"OPC-262 is a selective and potent inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"Oral Phosphate Supplement","genericName":"Oral Phosphate Supplement","slug":"oral-phosphate-supplement","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Poteligeo","genericName":"Poteligeo","slug":"poteligeo","phase":"marketed","mechanism":"C-C chemokine receptor type 4","indications":["Mycosis fungoides","Peripheral T-cell lymphoma","Primary cutaneous T-cell lymphoma"],"catalyst":""},{"name":"active vitamin D","genericName":"active vitamin D","slug":"active-vitamin-d","phase":"phase_3","mechanism":"Active vitamin D works by binding to vitamin D receptors in the body, which helps regulate calcium levels and bone health.","indications":["Treatment of hypocalcemia in patients with vitamin D deficiency or insufficiency"],"catalyst":""},{"name":"saxaglipitin","genericName":"saxaglipitin","slug":"saxaglipitin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-07","type":"earnings","headline":"Kyowa Kirin Announces FY2023 Financial Results","summary":"The company reported a net income of ¥34.4 billion for the fiscal year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-01","type":"deal","headline":"Kyowa Kirin Partners with AstraZeneca to Develop New Cancer Therapies","summary":"The partnership aims to develop novel cancer treatments using Kyowa Kirin's expertise in immunology.","drugName":"","sentiment":"positive"},{"date":"2023-08-25","type":"regulatory","headline":"Kyowa Kirin's Poteligeo Receives Approval in Japan for Additional Indication","summary":"The Japanese Ministry of Health, Labour and Welfare approved Poteligeo for the treatment of peripheral T-cell lymphoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNWG5SZjZpU2NFbC14OUV1dlJJVE51ZFdhNnhDWmNrSTllb0N4LXZJNWg5c3hQS2dyTWxlaWpCTmluMXF4TmhIYzI2RUU1NXlmX0FaMnRpMGlEaFF0eHJYc0kwMGtFd24zb25yU0dkQzl2SEl5NEFJQmZQSWF3VnhRZWxld3VMZzlobk9vVkREUThLb2lRWTNaRUJhSXU?oc=5","date":"2026-03-03","type":"trial","source":"Yahoo Finance","summary":"Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials - Yahoo Finance","headline":"Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-11","type":"pipeline","source":"simplywall.st","summary":"Kyowa Kirin Co., Ltd. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st","headline":"Kyowa Kirin Co., Ltd. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQd3d6RVZXLVFNV3ZjdWktN1Q0UjR1Unp1Mm1tLUZWZXUzUXU1TEhwa0t2MXBMM2NOenNOSDl4cHliOU1pWmdrU180OWhnUWZlLW5NQWZ5a2JZZU1NQWFDMWsxcXE1RjFnSy1hLUVwaUQwdk9HVmw1aHJjZ2dqMnNoM0Q2b1p0LVJoMUh5T1pCR1V0SmdXd3I5ZW5zMkxybUExY3RkZ0pJdHR1SzR2elhaYTFnNnlGQQ?oc=5","date":"2026-02-06","type":"pipeline","source":"Reuters","summary":"Japan's Kirin to sell Four Roses bourbon brand to Gallo for $775 million - Reuters","headline":"Japan's Kirin to sell Four Roses bourbon brand to Gallo for $775 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxNN0JnQmducElJclA0MkhPZjJ2NHlyZUpKQ0FSUVgwUHZxZVp6SVNrNzFVcmpDZGxUSHhRRXNOXzF0bzAzaWJVYk5INVdnSnFpUTVMVzgxSUZkWDhQMTdEeW9OU3VaUWYwYlF6ejJLbnVnQkV1YkFJeExEUjdRYkNsQzBPcVRxcmdOSzg1RHYwMEFrWVN1ckNEX1huSUsya1ZnZ09SVXYwTWhWOEFpazJnM2RidE1DeWJSb1d1VVlXcDZmcUJQeFBXVmZyNjVBSk5oNzA5NnE4ckM0ZTI3SDNhRWJWR0dScUJRa1lCZ1RGYk56T3Y3dkhXZUZJNGxHUFliLVNwWlB6bkpKNFAtbVR2WGNfdVJzT3pVVUdsV0c0ajlsRDZFSzVWLTFqX3k2ck5nVnk3UA?oc=5","date":"2025-12-11","type":"regulatory","source":"Business Wire","summary":"Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman - Business Wire","headline":"Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPY3ZZQVFvT0Iya2xMU3lqWHM2bzVJYVBUNnhtX2M1Vnc1bTdsdnlzSTYwZlB5MDJvaU5tZWNRbFpSbzlXNmNMUHlqbnpmaGl5OXRKOHdKWGF4aGVabjVGVno0VlRDMjN2SGVmSS1pRndRRVNXLU9zNGstSUFOY2ZPWjVhWU5ZQTkzemp6S1VyYXBJaDJzcHdnRGRNZnZCR0FhTTVIcFFMSGZnczlHVm10SGljS0lKMmJsc2xxQkN6ekg?oc=5","date":"2025-11-13","type":"regulatory","source":"Reuters","summary":"US FDA approves Kura-Kyowa's blood cancer therapy - Reuters","headline":"US FDA approves Kura-Kyowa's blood cancer therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPWVBmMTY4LV9sWl9rS0FaVzlkVUZTdmpBNWd0VXByajRCdFhNY19xczNwckQwb1B0aHFnbGwwT2NDWnU5ZlAtZEVaSV9HMEpWb0kzckJRWnBlcVlJaVlSa0pKSlBUcEY1aVd6TE9Nelo4ZE04ZE4tNU9hVXViZ3hZVmZhS2MxNEFPNG1Id09PX0FJNTRRQTNReXNGbTV2eUxTS0h4UVp6RXE4eldIWlhxZ1JoRzFwZFA0Vy13M3hhaw?oc=5","date":"2025-10-24","type":"pipeline","source":"Reuters","summary":"Japan's Kirin looks to sell Kentucky bourbon brand for $1 billion, FT reports - Reuters","headline":"Japan's Kirin looks to sell Kentucky bourbon brand for $1 billion, FT reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxPcjRfc0QydnNIVGJWQkdkdVYtV3g3NVhiLXkyNG1SYVU3cVlCVWJETEVYOEdNeGxGTXZwOFZaRWhfMS1VOXJ5RllGZkRZTGhsR1FGSmM2VDBST21uWVprOXJwcUs2QUNXUWdfYldpSmJBYTBBYTF3YUpnYXV5ZUN1d3ViZjNDMExBSTlDWndocU9sdmpGNXMteTdZdXdXeWdNckFZSFpZbjZIYzZsYkRxM0NzbXIwQUNoSElWV2g2YlhGLVBTUE45Z0dScFJvT2hlTUE3SDNaQXIxUndGZlhXRFhORmw2WktyWExXMVdkSElrWU1yYnFfUXVHc3MxUnItdEdZVS1xM0VLVW5iVTd3X2pfeDltWWNONlBYTWpPSVJNVl9RWGd6UEVMZ215LVlzR19rSDZyQnhYLWR4TmxoS181SHV0U2M?oc=5","date":"2025-10-22","type":"trial","source":"STT Info","summary":"Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab) - STT Info","headline":"Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9Bb1RaRVh4UkpwZ015TnluNWtFV1lncnB2Q2pRN19nRWowMmlHbjlFLW5rWGpWRTY5eUtUdjZMdFpKV2Z3Y2wwMGhTdkJzZnkyakZMQQ?oc=5","date":"2019-09-04","type":"pipeline","source":"Yahoo Finance UK","summary":"Sumitomo Pharma Co., Ltd. (4506.T) stock price, news, quote and history - Yahoo Finance UK","headline":"Sumitomo Pharma Co., Ltd. (4506.T) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5pVmxabnVWT2J6U1MwZDJQZ2hnQldIMjBzVDNWaGtOSUwxUG5BSDZPazRKZjlOMHRpQzJSRXAtcklJbHB2VnBxWFoxN1VMOTBFOUM1c0VqYkY?oc=5","date":"2017-08-05","type":"pipeline","source":"TradingView","summary":"4151 Stock Price and Chart — TSE:4151 - TradingView","headline":"4151 Stock Price and Chart — TSE:4151","sentiment":"neutral"}],"patents":[{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"8186511","type":"Formulation","expiryDate":"2026-07-19","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9205075","type":"Formulation","expiryDate":"2026-07-19","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9539241","type":"Compound","expiryDate":"2028-01-02","territory":"US","genericFilings":[]},{"drugName":"Poteligeo","drugSlug":"mogamulizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"7806265","type":"Formulation","expiryDate":"2029-02-01","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9649428","type":"Method of Use","expiryDate":"2029-05-21","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"10039832","type":"Method of Use","expiryDate":"2031-01-20","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9950069","type":"Formulation","expiryDate":"2031-01-20","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9040074","type":"Formulation","expiryDate":"2031-01-20","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"12268745","type":"Method of Use","expiryDate":"2031-01-20","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"12440568","type":"Method of Use","expiryDate":"2031-01-20","territory":"US","genericFilings":[]}],"drugCount":33,"phaseCounts":{"marketed":9,"phase_2":4,"phase_3":13,"phase_1":7},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Takeda Pharmaceutical","Eisai Co., Ltd.","Ono Pharmaceutical"],"therapeuticFocus":["Rare Diseases","Oncology","Nephrology"],"financials":{"source":"yahoo_finance","revenue":3141168175.7764,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":3141168175.7764},{"period":"2024-12-31","value":3133151282.0411997},{"period":"2023-12-31","value":2796005494.6362},{"period":"2022-12-31","value":2518689254.0894}],"grossProfit":2332309119.6888,"grossProfitHistory":[{"period":"2025-12-31","value":2332309119.6888},{"period":"2024-12-31","value":2294722027.2158},{"period":"2023-12-31","value":2092902417.6564},{"period":"2022-12-31","value":1969165329.8869998}],"rdSpend":639726623.6661999,"rdSpendHistory":[{"period":"2025-12-31","value":639726623.6661999},{"period":"2024-12-31","value":654653978.6416},{"period":"2023-12-31","value":455888122.7684},{"period":"2022-12-31","value":397658161.1744}],"sgaSpend":1045951733.5876,"operatingIncome":646630762.435,"operatingIncomeHistory":[{"period":"2025-12-31","value":646630762.435},{"period":"2024-12-31","value":580820157.6324},{"period":"2023-12-31","value":605958303.9188},{"period":"2022-12-31","value":520807259.10359997}],"netIncome":423858482.65599996,"netIncomeHistory":[{"period":"2025-12-31","value":423858482.65599996},{"period":"2024-12-31","value":378526362.718},{"period":"2023-12-31","value":513308808.0232},{"period":"2022-12-31","value":338713760.3122}],"eps":128.07,"epsHistory":[{"period":"2025-12-31","value":128.07},{"period":"2024-12-31","value":113.06},{"period":"2023-12-31","value":151.01},{"period":"2022-12-31","value":99.66}],"cash":1383160745.7066,"cashHistory":[{"period":"2025-12-31","value":1383160745.7066},{"period":"2024-12-31","value":1546988624.6234},{"period":"2023-12-31","value":2548480739.3262},{"period":"2022-12-31","value":2144544364.0516}],"totalAssets":7004413165.2039995,"totalLiabilities":1356347144.4991999,"totalDebt":null,"equity":5648066020.7048,"operatingCashflow":562187834.4166,"operatingCashflowHistory":[{"period":"2025-12-31","value":562187834.4166},{"period":"2024-12-31","value":429194648.5176},{"period":"2023-12-31","value":730574215.2128},{"period":"2022-12-31","value":307727327.9808}],"capex":-528046488.8566,"capexHistory":[{"period":"2025-12-31","value":-528046488.8566},{"period":"2024-12-31","value":-665553919.3352},{"period":"2023-12-31","value":-207705830.4328},{"period":"2022-12-31","value":-181239965.1524}],"freeCashflow":34141345.56,"dividendsPaid":-195250561.7748,"buybacks":-56902.2426,"employees":5161,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-03-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":11.78,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2363,"previousClose":2357.5,"fiftyTwoWeekHigh":2912,"fiftyTwoWeekLow":2109,"fiftyTwoWeekRange":"2109.0 - 2912.0","fiftyDayAverage":2427.05,"twoHundredDayAverage":2494.55,"beta":0.1,"enterpriseValue":6243304103.973027,"forwardPE":17,"priceToBook":1.39,"priceToSales":2.42,"enterpriseToRevenue":1.93,"enterpriseToEbitda":7.17,"pegRatio":4.79,"ebitda":870364091.0471299,"ebitdaMargin":27,"freeCashflow":231056293.37867057,"operatingCashflow":941687829.0008899,"totalDebt":0,"debtToEquity":0,"currentRatio":3.18,"returnOnAssets":6.6,"returnOnEquity":8.5,"analystRating":"3.5 - Hold","recommendationKey":"hold","numberOfAnalysts":11,"targetMeanPrice":2154.55,"targetHighPrice":3100,"targetLowPrice":1600,"dividendRate":70,"payoutRatio":0.48,"fiveYearAvgDividendYield":1.96,"exDividendDate":1782691200,"insiderHeldPercent":55,"institutionHeldPercent":18.5,"sharesOutstanding":523486836,"floatShares":229418106,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":128.01,"epsForward":138.74,"revenuePerShare":975.33,"bookValue":1705.37,"officers":[{"age":58,"name":"Dr. Abdul Hafeez  Mullick Ph.D.","title":"President, CEO & Representative Director"},{"age":null,"name":"Mr. Koji  Igarashi","title":"Chief Financial Officer"},{"age":null,"name":"Naohiko  Kubo","title":"Global Finance Head & Accounting Manager"},{"age":null,"name":"Kazuki  Nemoto","title":"Head of Global Legal"},{"age":null,"name":"Takaaki  Uochi Ph.D.","title":"Head of Global Compliance & Risk Management"},{"age":null,"name":"Stacey  Minton","title":"Global Corporate Communications Head"},{"age":null,"name":"Ms. Shoko  Itagaki","title":"Managing Executive Officer, Chief People Officer & Global Human Resources Head"},{"age":64,"name":"Mr. Takeyoshi  Yamashita Ph.D.","title":"Executive VP, Chief Scientific Officer & Director"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.kyowa-kirin.com/investors/index.html","website":"https://www.kyowakirin.com","phone":"81 3 5205 7200"}}